Ductal
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Development positions malignant cellular states but does notexplain their diversification
Epithelial cancers are often described as aberrant reactivations of embryonic or tissue-forming programs, but whether malignant cellular-state diversification is actually constrained by developmental trajectories remains unclear. Here, we present a quantitative framework to test this idea in pancreatic ductal adenocarcinoma (PDAC). Using representation learning on large-scale single-cell data, we build a reference space that captures the main axes of normal foregut and pancreatic epithelial...
Detection of Pancreatic Cancer Using a Methylation-Specific PCR-Based Multi-Cancer Early Detection Test
Context: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy often diagnosed at advanced stages due to the lack of early clinical symptoms. DNA methylation alterations arise early in PDAC tumorigenesis and may serve as promising biomarkers for blood-based cancer detection. Objective: To evaluate the performance of EPISEEK, a laboratory-developed blood-based multi-cancer early detection (MCED) assay, for detecting PDAC across disease stages.
Matched pancreatic cancer liver metastatic model system reveals cancer cell-dependent organotropism and site-specific tumor microenvironment reflective of human disease
Pancreatic ductal adenocarcinoma (PDAC) is a deadly, highly metastatic disease, driven by an interplay between cancer cells and the metastatic site-specific microenvironment. However, pre-clinical models that robustly capture these interactions within the context of matched primary and metastatic tumors are limited. Here, we present a novel transplant model system for matched pancreas and liver tumors to study PDAC metastatic progression.
X-Men actor Tyler Mane says he was diagnosed with breast cancer and urges men to get checked
Retired wrestler Tyler Mane, known for his role in the X-Men franchise, revealed Tuesday that he had been diagnosed with breast cancer. Mane posted a video on Instagram explaining that he was one of the “super rare” cases of breast cancer in men. In the caption he wrote that his initial reaction to the news was embarrassment.
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...
One fat helped pancreatic cancer grow while another cut disease in half
One fat helped pancreatic cancer grow while another cut disease in half - Date: - June 2, 2026 - Source: - Yale School of Medicine - Summary: - A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several other common foods—sped up tumor growth in mice predisposed to pancreatic cancer, while omega-3-rich fats from fish oil dramatically slowed disease...
Daily pill can double survival time for deadliest cancer, trial shows
A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades. Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late.